Orforglipron Reduced Sleep Apnea Events With and Without PAP

Key Takeaways
- Among adults with moderate to severe OSA and overweight or obesity in separate non-PAP and PAP trials, orforglipron was associated with significantly larger AHI reductions than placebo after 52 weeks.
- Six of seven key multiplicity-controlled secondary end points significantly favored orforglipron.
- Gastrointestinal adverse events were more common with orforglipron than placebo in both trials.
Recurrent upper-airway collapse during sleep defines obstructive sleep apnea (OSA), a condition associated with increased incidence of cardiometabolic disease. For adults with OSA and excess weight, the potential role of an oral treatment raises different questions depending on whether they receive positive airway pressure (PAP). Whether oral orforglipron affects sleep-disordered breathing in both groups was tested in separate comparisons.
Investigators randomized adults in the two phase 3 orforglipron trials, independent, multicenter, double-blind, placebo-controlled studies. The trials lasted 52 weeks at 66 sites in nine countries, including the US. Eligible adults had moderate to severe OSA and a body mass index (BMI) of at least 27. The trial without PAP randomized 363 participants, and the trial receiving PAP randomized 349.
Across the trials, 712 adults were randomized. Within each trial, participants were assigned 1:1 to once-daily oral orforglipron or placebo. The maximum tolerated tablet-equivalent orforglipron dose was 9, 14.5, or 17.2 mg. The primary end point was change from baseline in the apnea–hypopnea index (AHI), measured in events per hour; the reported primary comparison used the treatment-regimen estimand.
At week 52, mean AHI changed by −17.8 versus −4.5 events per hour with orforglipron versus placebo in the trial without PAP. In the trial receiving PAP, the corresponding AHI changes at week 52 were −17.3 versus −5.3 events per hour. For participants not receiving PAP, the treatment-regimen between-group difference in AHI change was −13.2 events per hour (95% confidence interval [CI], −17.7 to −8.7; P<.001). For participants receiving PAP, the treatment-regimen between-group difference in AHI change was −12.0 events per hour (95% CI, −17.1 to −6.9; P<.001).
Gastrointestinal adverse events occurred in 123 participants (68%) assigned to orforglipron in the trial without PAP. In that trial's placebo group, 68 participants (37.4%) reported gastrointestinal adverse events. In the trial receiving PAP, gastrointestinal adverse events occurred in 125 participants (70.6%) assigned to orforglipron. In the PAP trial's placebo group, 63 participants (36.6%) reported gastrointestinal adverse events.
The investigators concluded that oral orforglipron has potential to improve sleep-disordered breathing in adults with moderate to severe OSA and overweight or obesity.
Clinician Questions
Which secondary measures did the orforglipron obstructive sleep apnea trials assess beyond AHI?
For adults with moderate to severe obstructive sleep apnea and overweight or obesity, examples among the key multiplicity-controlled secondary end points included sleep apnea–specific hypoxic burden, the Patient-Reported Outcomes Measurement Information System Short Form Sleep-Related Impairment T-score, and high-sensitivity C-reactive protein.
Was oral orforglipron tested as a replacement for positive airway pressure in obstructive sleep apnea?
No. Adults with moderate to severe obstructive sleep apnea and overweight or obesity who were receiving positive airway pressure entered a separate randomized orforglipron-versus-placebo trial, while adults not receiving positive airway pressure entered the other trial. Neither trial directly compared an oral replacement strategy with positive airway pressure or established that positive airway pressure could be stopped.
This content is intended for healthcare professionals for educational purposes. The article and its image were developed with AI assistance and reviewed by members of the ReachMD team prior to publication. Please refer to the original source linked for the complete and most up-to-date information.